The historical rank and industry rank for Pacira BioSciences's Net Cash per Share or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Cash Ratio of Pacira BioSciences was 116.27. The lowest was 116.27. And the median was 116.27.
PCRX's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 8.4 * Ranked among companies with meaningful Price-to-Net-Cash only.
Pacira BioSciences Net Cash per Share Historical Data
The historical data trend for Pacira BioSciences's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pacira BioSciences's Net Cash per Share
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Pacira BioSciences's Net Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences (NAS:PCRX) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Pacira BioSciences Net Cash per Share Related Terms
Thank you for viewing the detailed overview of Pacira BioSciences's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PCRX has been successfully added to your 